Network Portfolio

Opinion/decision on a Paediatric investigation plan (PIP): Qdenga, Dengue tetravalent vaccine (live, attenuated), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0003/2024

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024

Human medicines European public assessment report (EPAR): Zolsketil pegylated liposomal, doxorubicin, Date of authorisation: 31/05/2022, Revision: 4, Status: Authorised

European Shortages Monitoring (ESMP) - Question and answer clinic for marketing authorisation holders on shortage reporting via ESMP, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 February 2025, 10:00 (CET) to 25 February 2025, 11:00 (CET)

EMEA-000205-PIP02-11-M06

Release notes - production release version 1.7.2514 - 12 March 2025 - Veterinary Medical Products Regulation: Union Product Database

EMEA-001213-PIP03-23

Network Portfolio Roadmap

High-risk medical devices: consultation procedures and advice